JP2013521226A5 - - Google Patents

Download PDF

Info

Publication number
JP2013521226A5
JP2013521226A5 JP2012555127A JP2012555127A JP2013521226A5 JP 2013521226 A5 JP2013521226 A5 JP 2013521226A5 JP 2012555127 A JP2012555127 A JP 2012555127A JP 2012555127 A JP2012555127 A JP 2012555127A JP 2013521226 A5 JP2013521226 A5 JP 2013521226A5
Authority
JP
Japan
Prior art keywords
composition
mixture
apixaban
granulation
tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012555127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013521226A (ja
JP5846647B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/025994 external-priority patent/WO2011106478A2/en
Publication of JP2013521226A publication Critical patent/JP2013521226A/ja
Publication of JP2013521226A5 publication Critical patent/JP2013521226A5/ja
Application granted granted Critical
Publication of JP5846647B2 publication Critical patent/JP5846647B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012555127A 2010-02-25 2011-02-24 アピキサバン製剤 Active JP5846647B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30805610P 2010-02-25 2010-02-25
US61/308,056 2010-02-25
PCT/US2011/025994 WO2011106478A2 (en) 2010-02-25 2011-02-24 Apixaban formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015226794A Division JP6033945B2 (ja) 2010-02-25 2015-11-19 アピキサバン製剤

Publications (3)

Publication Number Publication Date
JP2013521226A JP2013521226A (ja) 2013-06-10
JP2013521226A5 true JP2013521226A5 (enExample) 2014-04-10
JP5846647B2 JP5846647B2 (ja) 2016-01-20

Family

ID=43901603

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2012555127A Active JP5846647B2 (ja) 2010-02-25 2011-02-24 アピキサバン製剤
JP2015226794A Active JP6033945B2 (ja) 2010-02-25 2015-11-19 アピキサバン製剤
JP2016209347A Active JP6192078B2 (ja) 2010-02-25 2016-10-26 アピキサバン製剤
JP2017149644A Active JP6577980B2 (ja) 2010-02-25 2017-08-02 アピキサバン製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2015226794A Active JP6033945B2 (ja) 2010-02-25 2015-11-19 アピキサバン製剤
JP2016209347A Active JP6192078B2 (ja) 2010-02-25 2016-10-26 アピキサバン製剤
JP2017149644A Active JP6577980B2 (ja) 2010-02-25 2017-08-02 アピキサバン製剤

Country Status (31)

Country Link
US (5) US9326945B2 (enExample)
EP (7) EP3017811B1 (enExample)
JP (4) JP5846647B2 (enExample)
KR (4) KR20170126016A (enExample)
CN (3) CN102770126A (enExample)
AU (1) AU2011220775B2 (enExample)
BR (1) BR112012021337A8 (enExample)
CA (1) CA2791171C (enExample)
CO (1) CO6640207A2 (enExample)
CY (5) CY1117434T1 (enExample)
DK (5) DK3251660T3 (enExample)
ES (5) ES2714363T3 (enExample)
HK (2) HK1243947B (enExample)
HR (5) HRP20160179T1 (enExample)
HU (4) HUE047139T2 (enExample)
IL (3) IL309564A (enExample)
IN (1) IN2012DN06587A (enExample)
LT (4) LT3251660T (enExample)
MX (3) MX353145B (enExample)
NZ (1) NZ601738A (enExample)
PE (3) PE20210468A1 (enExample)
PL (5) PL2538925T3 (enExample)
PT (5) PT3017811T (enExample)
RS (5) RS59593B1 (enExample)
RU (1) RU2685724C2 (enExample)
SG (2) SG182750A1 (enExample)
SI (5) SI2538925T1 (enExample)
SM (5) SMT201900212T1 (enExample)
TR (1) TR201903195T4 (enExample)
WO (1) WO2011106478A2 (enExample)
ZA (1) ZA201205807B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL309564A (en) * 2010-02-25 2024-02-01 Pfizer Preparations containing apixaban
WO2013164839A2 (en) * 2012-03-06 2013-11-07 Cadila Healthcare Limited Amorphous form of apixaban, process of preparation and compositions thereof
EP2854759B1 (en) * 2012-05-24 2019-12-18 ratiopharm GmbH Dosage forms comprising apixaban and matrix former
RU2660358C2 (ru) * 2012-09-26 2018-07-05 Бристол-Майерс Сквибб Холдингс Айеленд Жидкие лекарственные композиции апиксабана
CN102908324A (zh) * 2012-10-31 2013-02-06 南京正科制药有限公司 一种阿哌沙班片
EP2752414A1 (en) 2013-01-04 2014-07-09 Sandoz AG Crystalline form of apixaban
CZ2013305A3 (cs) 2013-04-23 2014-11-05 Zentiva, K.S. Nové krystalické formy APIXABANU a způsob jejich přípravy
WO2014203275A2 (en) * 2013-06-18 2014-12-24 Cadila Healthcare Limited An improved process for the preparation of apixaban and intermediates thereof
EP2907507A1 (en) 2014-02-17 2015-08-19 Sandoz Ag Pharmaceutical composition comprising apixaban
CN103830199A (zh) * 2014-03-24 2014-06-04 重庆东得医药科技有限公司 含阿哌沙班的药用制剂及其制备方法
SG10201900648SA (en) 2014-07-25 2019-02-27 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
CN104316637B (zh) * 2014-10-30 2016-08-17 江苏宝众宝达药业有限公司 高效液相色谱法测定阿哌沙班清洗残留量
US9603846B2 (en) 2014-11-25 2017-03-28 Cadila Healthcare Limited Process for the preparation of apixaban
AU2016259897A1 (en) * 2015-05-08 2017-08-17 Wockhardt Limited Stable pharmaceutical compositions comprising antibacterial agent
WO2017088841A1 (en) 2015-11-26 2017-06-01 Zentiva, K.S. Preparation of a drug form containing amorphous apixaban
CN106913528A (zh) * 2015-12-25 2017-07-04 中美华世通生物医药科技(武汉)有限公司 阿哌沙班微丸及其制备方法
US10537524B2 (en) * 2016-01-12 2020-01-21 North & South Brother Pharmacy Investment Company Limited Apixaban solid composition and preparation method thereof
EP3195860A1 (de) * 2016-01-22 2017-07-26 STADA Arzneimittel AG Verfahren zur herstellung eines apixaban-granulates
WO2017163170A1 (en) * 2016-03-21 2017-09-28 Sun Pharmaceutical Industries Limited Pharmaceutical composition comprising apixaban
WO2017182908A1 (en) * 2016-04-18 2017-10-26 Emcure Pharmaceuticals Limited Pharmaceutical compositions of apixaban
EP3243505A1 (en) 2016-05-13 2017-11-15 Zaklady Farmaceutyczne Polpharma SA A pharmaceutical composition comprising amorphous apixaban
CN106822006B (zh) * 2016-06-08 2020-08-28 北京普德康利医药科技发展有限公司 一种阿哌沙班片及其制备方法
WO2017221209A1 (en) 2016-06-23 2017-12-28 Lupin Limited Pharmaceutical formulations of apixaban
WO2018054357A1 (zh) * 2016-09-24 2018-03-29 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途
CN106420651B (zh) * 2016-09-28 2019-03-08 乐普药业股份有限公司 一种阿哌沙班片的制备方法
EP3582777A4 (en) 2017-02-17 2020-12-23 Unichem Laboratories Ltd PHARMACEUTICAL COMPOSITION OF APIXABAN
JP7044115B2 (ja) 2017-11-27 2022-03-30 三菱ケミカル株式会社 ゴム含有グラフト重合体組成物を含む熱可塑性樹脂の樹脂改質用組成物、ゴム含有グラフト重合体含有樹脂組成物およびその成形体
KR20190075566A (ko) 2017-12-21 2019-07-01 전자부품연구원 다중 센서를 활용한 용변 습관 모니터링 시스템 및 방법
TR201722523A2 (tr) 2017-12-28 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren kati oral farmasöti̇k kompozi̇syonlar
CN108236604A (zh) * 2018-02-07 2018-07-03 中国药科大学 阿哌沙班柔性脂质体
MX2020010673A (es) 2018-04-16 2020-10-28 Bristol Myers Squibb Co Formulaciones de apixaban.
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
WO2020034989A1 (zh) 2018-08-14 2020-02-20 江苏恒瑞医药股份有限公司 一种可注射的药物组合物及其制备方法
EP3666773A1 (en) 2018-12-11 2020-06-17 KRKA, D.D., Novo Mesto Process for preparing apixaban
EP3669866A1 (en) 2018-12-19 2020-06-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apixaban
CN111377915B (zh) * 2018-12-30 2023-10-24 鲁南制药集团股份有限公司 一种吡唑并-吡啶酮化合物晶型d
CN109464415B (zh) * 2019-01-09 2021-08-17 常州恒邦药业有限公司 阿哌沙班药物组合物及其制备方法
KR20220101103A (ko) 2019-11-13 2022-07-19 유니슨 파마슈티컬스 피브이티. 엘티디. 아픽사반의 구강 붕해성 약학적 조성물
CN111214442B (zh) * 2020-02-13 2021-12-10 山东百诺医药股份有限公司 一种阿哌沙班共微粉化物
CN111494326A (zh) * 2020-04-11 2020-08-07 南京正大天晴制药有限公司 一种阿哌沙班片及其制备方法
EP4251155A4 (en) 2020-11-27 2024-07-31 Santa Farma Ilac Sanayii A.S. IMPROVED WET GRANULATION PROCESSES FOR APIXABAN WITH FORMULATIONS
EP4251271A4 (en) 2020-11-27 2024-07-31 Santa Farma Ilac Sanayii A.S. Direct compression method for non-micronised apixaban formulations
TR202100250A2 (tr) 2021-01-08 2022-07-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Api̇ksaban i̇çeren fi̇lm kapli tablet
WO2022150030A2 (en) 2021-01-08 2022-07-14 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A film coated tablet of apixaban
JP2022112698A (ja) * 2021-01-22 2022-08-03 東和薬品株式会社 アピキサバン含有医薬組成物
GB202102575D0 (en) 2021-02-23 2021-04-07 Teva Pharmaceutical Industries Ltd Fixed-dose pharmaceutical compositions
AU2022288053B2 (en) * 2021-06-08 2025-08-07 Taho Pharmaceuticals Ltd. Apixaban film product and uses thereof
AU2022374714B2 (en) 2021-10-27 2024-05-23 Pharma-Data Research And Development Single Member S.A. Apixaban suspension and preparation method
JP7834007B2 (ja) * 2022-10-12 2026-03-23 日本ジェネリック株式会社 アピキサバンを含有する錠剤
JP2024064876A (ja) * 2022-10-28 2024-05-14 ニプロ株式会社 医薬組成物
KR102760108B1 (ko) 2024-04-09 2025-01-24 에바바이오 주식회사 수용해도와 투과도를 향상시켜 생체이용률이 개선된 무정형 아픽사반 고체분산체 제제 및 그의 서방성 정제
JP7854233B2 (ja) * 2024-10-10 2026-05-01 富士化学工業株式会社 アピキサバン含有組成物、アピキサバン含有固形製剤、及びアピキサバン含有固形製剤の製造方法
EP4759304A1 (en) 2024-12-10 2026-06-17 Laboratoires S.M.B. Pellet compositions comprising apixaban and methods for the production thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150366A (en) 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
NZ511674A (en) 1998-12-23 2003-11-28 Du Pont Pharm Co Nitrogen containing heterobicycles as factor Xa inhibitors
AU2002341693B2 (en) 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20070025991A1 (en) * 2003-03-19 2007-02-01 Charalabos Pothoulakis Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US20050059719A1 (en) * 2003-09-16 2005-03-17 Badawy Sherif Ibrahim Farag Solid dosage formulation containing a Factor Xa inhibitor and method
DE10355461A1 (de) * 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
US7434502B2 (en) 2004-07-21 2008-10-14 Husqvarna Outdoor Products Inc. Bar knob with cam-operated locking mechanism
US20060016084A1 (en) * 2004-07-24 2006-01-26 Ching-Lin Liao Laser-Based datum instrument
US7396932B2 (en) 2004-09-28 2008-07-08 Bristol-Myers Squibb Company Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US20060160841A1 (en) * 2005-01-19 2006-07-20 Chenkou Wei Crystallization via high-shear transformation
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
US9034381B2 (en) 2005-11-10 2015-05-19 Alphapharm Pty Ltd Process to control particle size
US20070259913A1 (en) 2006-05-04 2007-11-08 David Deitchman Prophylaxis of thromboembolic events in cancer patients
US20090285887A1 (en) * 2006-09-12 2009-11-19 Omar Abdelfattah Abu-Baker Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor
FI20080351A0 (fi) 2008-05-09 2008-05-09 Atacama Labs Oy Prosessi matalan lääkepitoisuuden tabletin valmistamiseksi
KR101509829B1 (ko) * 2007-05-02 2015-04-06 포톨라 파마슈티컬스, 인코포레이티드 혈소판 adp 수용체 억제제로 작용하는 화합물을 이용한 병용요법
US20090143343A1 (en) * 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2009135946A1 (en) * 2008-05-09 2009-11-12 Atacama Labs Oy Method and apparatus for dry granulation
CN102089051A (zh) 2008-07-11 2011-06-08 巴斯夫欧洲公司 作为形态学改变剂的两亲性蛋白质
US20100018486A1 (en) * 2008-07-22 2010-01-28 Hung-Tao Liu Cathode energy fuel-saving device
CN107233337A (zh) * 2009-04-29 2017-10-10 阿马里纳药物爱尔兰有限公司 含有epa和心血管剂的药物组合物以及使用其的方法
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
IL309564A (en) * 2010-02-25 2024-02-01 Pfizer Preparations containing apixaban
AU2011225810B2 (en) * 2010-03-10 2014-11-06 Lupin Limited Rifaximin ready-to-use suspension

Similar Documents

Publication Publication Date Title
HRP20160179T1 (hr) Formulacije apiksabana
ES2688889T3 (es) Proceso de mezcla sin disolvente para el recubrimiento de ingredientes farmacéuticos
RU2221553C2 (ru) Способ изготовления округлых гранул
JP2015535289A5 (enExample)
JP2010508929A5 (enExample)
JP2011525501A5 (enExample)
JP2012509329A5 (enExample)
TW202510884A (zh) 包含Akt蛋白質激酶抑制劑之醫藥組合物
JP2009503156A5 (enExample)
WO2014200347A1 (en) Extended release nicotinamide formulation
CA2597688C (en) Agglomerated starch compositions
Zhai et al. Gastroretentive extended-release floating granules prepared using a novel fluidized hot melt granulation (FHMG) technique
CN102885791A (zh) 一种制备盐酸非索非那定口腔崩解片的方法
CN102349915A (zh) 一种氨酚咖敏维c制剂及其制备方法
Chew et al. A review on the development of granulation technology in the past two decades
CN105434375A (zh) 一种左乙拉西坦片剂及制备方法
CN101340896A (zh) 含有低溶解性药物的压缩的固体剂型和其制备方法
RU2576438C1 (ru) Способ получения гранулированного регенеративного продукта с применением вальцового компактора
Samanta et al. Energy-based analysis of cone milling process for the comminution of roller compacted flakes
CN102166361A (zh) 一种速崩型微丸丸芯及制备方法
RU2697660C2 (ru) Таблетка и способ ее получения
JP2017081859A (ja) テルミサルタン含有錠剤の製造方法
JP2015522629A (ja) 薬用粘土製剤
JP6285952B2 (ja) 高含量のイブプロフェンナトリウム顆粒、これらの調製、及び非発泡性固体剤形の調製におけるこれらの使用
CN109364037B (zh) 拉呋替丁片剂及其制备方法